The observation that MICA-ICs formed with α3 domain-specific antibodies agonized NKG2D in tumor-free conditions suggests that the agonistic properties of MICA-ICs is not unique to a particular tumor type (Fig. 5), and that MICA-ICs formed within a tumor mass can potentially activate NK-mediated anti-tumor responses. This evidence concerns the gene KLRK1 and neoplasm.